B&K CORPORATION LIMITED (“the Company”) is an innovative China-based biopharmaceutical company with a global vision. Since its establishment in 2012, the company has been consistently dedicated to addressing unmet clinical needs and developing innovative protein therapeutics. We firmly believe that genuine innovation stems from profound disease insights and clear clinical positioning. We are deeply focused on the large and continuously expanding specialized field of wound healing and tissue repair, and are fully advancing the R&D and commercialization of our core products - platelet-derived growth factor (PDGF) drugs. Our mission is to tackle the practical challenges faced by patients with chronic and acute wounds, and bring benefits to more patients worldwide.

As for now, we have built a diversified pipeline consisting of ten drug candidates. Of these, our two core products are as follows: Pro-101-1 for the treatment of deep second-degree thermal burns has completed the statistical data analysis for Phase IIb clinical trial, and for the treatment of superficial second-degree thermal burns has reached last-patient-out; Pro-101-2 for the treatment of diabetic foot ulcers (“DFUs”)  is currently in Phase II clinical trial.